{"denoms":[{"counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"150"}],"units":"Participants"}],"groups":[{"description":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- Controls from Phase A. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG000","title":"qHPV (GARDASIL™) - Phase A Control"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate(AAHS) and 15 mcg ISCOMATRIX™ (IMX). A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG001","title":"Octavalent HPV With 15 mcg IMX / AAHS"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG002","title":"Octavalent HPV With 30 mcg IMX / AAHS"},{"description":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)- Controls from Phase B. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG003","title":"qHPV (GARDASIL™) - Phase B Control"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG004","title":"Octavalent HPV With 60 mcg IMX / AAHS"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX. A 0.5-mL intramuscular injection was administered at Day 1, Month 2 and Month 6.","id":"BG005","title":"Octavalent HPV With 120 mcg IMX / AAHS"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.6","value":"20.3"},{"groupId":"BG001","spread":"1.8","value":"20.8"},{"groupId":"BG002","spread":"1.5","value":"20.2"},{"groupId":"BG003","spread":"1.6","value":"19.9"},{"groupId":"BG004","spread":"1.8","value":"20.5"},{"groupId":"BG005","spread":"2.0","value":"20.8"},{"groupId":"BG006","spread":"1.7","value":"20.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"150"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"30"},{"groupId":"BG005","value":"30"},{"groupId":"BG006","value":"150"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}